Inarigivir

Research use only, not for human use.

Inarigivir (ORI-9020, SB-9000) is a dinucleotide that activates RIG-I and NOD2.

Inarigivir (ORI-9020, SB-9000) is a dinucleotide that activates RIG-I and NOD2, induces interferon mediated antiviral immune responses; shows broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, RSV and influenza, and also demonstrates activity HBV in vitro and in vivo; a novel agonist of innate immunity; activite componet of Inarigivir soproxil (SB-9200).

Inarigivir (SB 9200) is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B.

Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values. Animal Model:MiceDosage:100 mg/kg.Administration:IP, daily.Result:Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control.

ORI-9020 | SB-9000

Immunology/Inflammation

RLR

RLR

Infection

——

475650-36-3

587.5008

C20H26N7O10PS

>98% (HPLC)

In Vitro:?DMSO : 200 mg/mL (340.43 mM)

O=P(OC[C@H]1O[C@@H](N2C=NC3=C(N)N=CN=C23)C[C@@H]1O)(S)O[C@@H]4[C@@H](CO)O[C@@H](N(C(N5)=O)C=CC5=O)[C@@H]4OC

O-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl) O-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-yl) S-hydrogen phosphorothioate

(-20℃)

With Ice Pack

≥ 2 years